Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer

Bitenc, Marko; Cufer, Tanja; Kern, Izidor; Miklavcic, Martina; Petrovic, Sabrina; Groznik, Vida; Sadikov, Aleksander

doi:10.2478/raon-2022-0030

Abstract

Background

Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I–IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010–2017.

Patients and methods

Data of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA).

Results

With a median follow-up of 53.9 months, median OS and 5-year OS rate in the overall population were 90.4 months and 64.4%. Five-year OS rates by pTNM stage I, II and IIIA were 70.2%, 60.21%, and 49.9%, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p = 0.003) in MVA. Agreement between cTNM and pTNM was 69.0%. Next to pTNM, age (p = 0.001) and gender (p = 0.004) retained their independent prognostic value for OS.

Conclusions

The study showed favourable outcomes of resectable stage I–IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660
Open DOI Search in Google Scholar Back to article
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75. doi: 10.1016/S0140-6736(17)33326-3
Open DOI Search in Google Scholar Back to article
Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. [Survival of cancer patients]. [Slovenian]. Ljubljana; Institute of Oncology; 2020
Search in Google Scholar Back to article
Montagne F, Guisier F, Venissac N, Baste JM. The role of surgery in lung cancer treatment: present indications and future perspectives – state of the art. Cancers 2021; 13: 1-24. doi: 10.3390/cancers13153711
Open DOI Search in Google Scholar Back to article
Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 2021; 32: 1637-42. doi: 10.1016/J.ANNONC.2021.08.1994
Open DOI Search in Google Scholar Back to article
Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer. Lung Cancer Targets Ther 2021; 12: 51-60. doi: 10.2147/LCTT.S277717
Open DOI Search in Google Scholar Back to article
The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365: 395-409. doi: 10.1056/NEJMOA1102873/SUPPL_FILE/NEJMOA1102873_DISCLOSURES.PDF
Open DOI Search in Google Scholar Back to article
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382: 503-13. doi: 10.1056/nejmoa1911793
Open DOI Search in Google Scholar Back to article
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016/j.jtho.2015.09.009
Open DOI Search in Google Scholar Back to article
Taber S, Pfannschmidt J. Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients. Innov Surg Sci 2020; 5: 1-9.doi: 10.1515/iss-2020-0010
Open DOI Search in Google Scholar Back to article
Cai B, Fulcher N, Boyd M, Spira A. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study. Thorac Cancer 2021; 12: 2055-64. doi: 10.1111/1759-7714.14007
Open DOI Search in Google Scholar Back to article
Abrão FC, Moreira FR, de Abreu IRLB, Marciano MG, Younes RN. Real-life long-term cohort of patients with stage IIIA non-small-cell lung cancer: overall survival related to patients’ characteristics and multiple treatment models. JCO Glob Oncol 2021; 7: 1572-85. doi: 10.1200/go.21.00219
Open DOI Search in Google Scholar Back to article
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, et al. The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg 2018; 42: 161-71. doi: 10.1007/s00268-017-4165-6
Open DOI Search in Google Scholar Back to article
Yun JK, Bok JS, Lee GD, Kim HR, Kim YH, Kim DK, et al. Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer. Eur J Cardio-Thoracic Surg 2020; 58: 59-69. doi: 10.1093/ejcts/ezaa042
Open DOI Search in Google Scholar Back to article
Crinò L, Weder W, van Meerbeeck J, Felip, ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103-15. doi: 10.1093/annonc/mdq207
Open DOI Search in Google Scholar Back to article
Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6:) vi89-98. doi: 10.1093/annonc/mdt241
Open DOI Search in Google Scholar Back to article
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1a
Open DOI Search in Google Scholar Back to article
Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681-90. doi: 10.1093/annonc/mdu145
Open DOI Search in Google Scholar Back to article
Heineman DJ, Beck N, Wouters MW, van Brakel TJ, Daniels JM, Schreuers WH, et al. The dutch national clinical audit for lung cancer: a tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLSA). Eur J Surg Oncol 2018; 44: 830-4. doi: 10.1016/J.EJSO.2017.12.002
Open DOI Search in Google Scholar Back to article
Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. doi: 10.2478/V10019-009-0008-X
Open DOI Search in Google Scholar Back to article
Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung Cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/J.JTHO.2019.02.025
Open DOI Search in Google Scholar Back to article
Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 2013; 6: 1507-13. doi: 10.3892/ol.2013.1566
Open DOI Search in Google Scholar Back to article
Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004; 78: 209-15. doi: 10.1016/J.ATHORACSUR.2003.11.021.
Open DOI Search in Google Scholar Back to article
Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer. JAMA Netw Open 2021; 4: e2131892. doi: 10.1001/jamanetworko-pen.2021.31892
Open DOI Search in Google Scholar Back to article
Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study. J Thorac Oncol 2015; 10: 1370-4. doi: 10.1097/JTO.0000000000000621
Open DOI Search in Google Scholar Back to article
Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4
Open DOI Search in Google Scholar Back to article